Clinical pharmacology of recombinant human luteinizing hormone: Part I. Pharmacokinetics after intravenous administration to healthy female volunteers and comparison with urinary human luteinizing hormone

Cotonnec, Jean-Yves le; Porchet, HervéClaude; Beltrami, Vanya; Munafo, Alain

doi:10.1016/s0015-0282(97)00501-3

Cited by 75 publications

(40 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One trial used a fixed 2:1 ratio of rec-hFSH and rec-hLH while another used a fixed dose of 75 IU rec-hLH regardless of the FSH dose; in both of them LH supplementation was given from the first day of stimulation on. Implantation (OR = 1.36; 95 % CI: 1.05 to 1.78, I 2 = 12 %) and clinical pregnancy rates (OR = 1.37; 95 % CI: 1.03 to 1.83, I 2 = 28 %) were significantly higher for women who received rec-hLH in addition to rec-hFSH compared with those in whom rec-hFSH was administered alone [92].…”

Section: Clinical Studies On Lh Supplementation During Cos In Selectementioning

confidence: 96%

“…At present, rec-hLH is used not only to support follicular development during COS in hypogonadotropic hypogonadic woman but also in other categories of female infertility [2,91,92]. Recombinant LH has three major differences compared to urinary products.…”

Section: ; [3])mentioning

confidence: 99%

“…Nevertheless, ovarian response to COS with FSH onlycontaining gonadotropins has been poor in a subset of normogonadotropic women including those in advanced reproductive age (≥ 35 years old; [92,142]), diminished ovarian reserve [91,140], and highly suppressed levels of endogenous LH, in whom LH activity falls below the LH threshold [143][144][145][146][147]. In addition, early studies identified a subgroup of normogonadotropic patients who had normal estimated ovarian reserve but suboptimal responses to FSH stimulation [148][149][150][151].…”

Section: Rationale Of Lh Supplementation: To Whom and Why?mentioning

confidence: 99%

See 2 more Smart Citations

Gonadotropin in Assisted Reproduction: An Evolution Perspective

Leão¹,

Esteves²

2015

Unexplained Infertility

View full text Add to dashboard Cite

Section: Clinical Studies On Lh Supplementation During Cos In Selectementioning

confidence: 96%

Section: ; [3])mentioning

confidence: 99%

Section: Rationale Of Lh Supplementation: To Whom and Why?mentioning

confidence: 99%

See 1 more Smart Citation

Gonadotropin in Assisted Reproduction: An Evolution Perspective

Leão¹,

Esteves²

2015

Unexplained Infertility

View full text Add to dashboard Cite

“…After subcutaneous administration, recombinant human LH is eliminated with a terminal half-life of approximately 24 hours in contrast to 5-7 days of hCG. 17,31 It has been shown that the expression of the LH/hCG receptor gene, as well as genes involved in the biosynthesis of cholesterol and steroids in granulosa cells, are lower in patients treated with hMG preparations. 32 Such effects are caused by a constant ligand exposure during the follicular phase due to longer half-life and higher binding affinity of hCG compared with rec-hLH.…”

Section: 321mentioning

confidence: 99%

Efficacy, efficiency and effectiveness of gonadotropin therapy for infertility treatment

Esteves¹

2015

Medical Express

View full text Add to dashboard Cite

Gonadotropin therapy is an essential element in infertility treatments involving assisted reproductive technology. In recent years there have been outstanding advances in the development of new gonadotropins, particularly with the production of gonadotropins using biotechnological resources. Recombinant gonadotropins have higher specific activity compared with urinary counterparts, thus allowing subcutaneous administration of minimal amounts of glycoprotein. As a result, recombinant formulations have a better safety profile despite an overall similarity in terms of efficacy for pregnancy, as reported in many randomized controlled trials and meta-analyses. Gonadotropins stimulate the ovaries to develop follicles and oocytes, which are the raw material for fertilization and embryo production. The resulting embryos are transferred (fresh or frozen-thawed) to achieve pregnancy. The efficiency of a gonadotropin should therefore measured by the amount of drug used, the number of oocytes/embryos produced, and the number of pregnancies achieved by transferring fresh and/or frozen-thawed embryos to the uterus (cumulative pregnancy). Comparisons between different gonadotropin preparations should also take into account other important quality indicators in reproductive medicine, such as safety and patient-centeredeness. Altogether, the aforementioned quality indicators favor biotech gonadotropins over biologic products in infertility therapy.

show abstract

“…The pharmacodynamics of recombinant and urinary derived LH preparations show similar clearance, half-life, and concentration curves (16,81). The pharmacodynamics profiles of rLH are similar whether it is administered subcutaneously or intramuscular and it does not impact the pharmacodynamics of co-administered rFSH (82)(83)(84). In hypogonadotropic hypogonadal patients, a dose of 75IU of rLH has been demonstrated to promote adequate folliculogenesis when administered with FSH (85).…”

Section: Recombinant Luteinizing Hormonementioning

confidence: 99%